Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Researchers observed persistent anti-RBD antibodies at 6 months after the second dose of an mRNA COVID-19 vaccine and a 20-fold increase in anti-RBD antibodies after the third dose.
The risk of neurologic adverse events was 41% lower in patients treated with immune checkpoint inhibitors than in patients who received another drug regimen or a placebo.
Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.